HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Q4 update

This article was originally published in The Rose Sheet

Executive Summary

Sales projected to grow 6%-7% in the fourth quarter (ending June 30) with foreign exchange expected to contribute 3%-4% to the top line and acquisitions and divestitures to have a negative 1% impact, Procter & Gamble reports June 5. Sales expectations have been adjusted to reflect impact of a tornado that struck firm's Jackson, Tenn. Pringles manufacturing facility in May. Core earnings per share, excluding restructuring charges, are expected to grow 12%. Separately, P&G says it is launching additional tender offer period for Wella shareholders June 6 and will not change offer price for voting shares and preference shares during that period. P&G acquired approximately 5 mil. voting shares and 1.5 mil. preference shares, representing total of 9.69% of registered share capital during initial tender period...

You may also be interested in...



No To Grapefruit Mask? Natural Player Yes To, Inc. Issues Recall Following ‘Chemical Burn’ Reports

Yes To is investigating reports – including posts on leading social media platforms – regarding irritation and redness experienced by children and other users of its Yes To Grapefruit Glow-Boosting Unicorn Paper Mask. In the meantime, the company is recalling the product voluntarily.

Warning Letter Roundup & Recap – 21 January 2020

A maker of low-level LED light-therapy devices was cited by the US FDA for premarket, quality systems and Medical Device Reporting violations. It's just one of two device-related warning letters released by the agency this week.

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 6)

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this sixth installment of a 10-part series, experts David Elder and John McKay address communication between the front room – where investigators do the majority of their work – and the back room, used by company workers to fulfill investigator requests for documents, records and other information.

UsernamePublicRestriction

Register

RS011268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel